

**Form 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Company

THC BioMed Intl Ltd. (the “**Issuer**”)
Suite 1100 – 888 Dunsmuir Street
Vancouver, BC V6C 3K4

Item 2: Date of Material Change

September 7, 2016

Item 3: News Release

A news release was issued and disseminated on September 7, 2016 and filed on SEDAR (www.sedar.com) and the Canadian Securities Exchange (the “**CSE**”). A copy of the news release is attached as Schedule “A” hereto.

Item 4: Summary of Material Change

The Issuer announced the appointment of Hee Jung Chun, as its interim Chief Financial Officer. Hee Jung is one of the original founders of THC.

Tracey St. Denis resigns from the position as CFO but will remain with the Issuer as its chief accountant.

Item 5: Full Description of Material Change

Please see the attached Schedule “A”.

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7: Omitted Information

None


Item 8: Executive Officer

John Miller, CEO and President
Email: info@thcbiomed.com

Item 9: Date of Report

September 12, 2016

Schedule "A"



THC BIOMED INTL LTD.
Suite 1500 – 888 Dunsmuir Street
Vancouver, BC V6C 3K4
www.thcbiomed.com

THC Appoints Chief Financial Officer

THC.CSE

THCBF – OTC

TFHC.F

Vancouver, B.C. – (September 7, 2016) THC BioMed Intl Ltd. (“**THC**” or the “**Company**”) is pleased to announce the appointment of Hee Jung Chun, as its interim Chief Financial Officer. Hee Jung is one of the original founders of THC.

“I am pleased to take this interim position as we ready ourselves to become a major player in the Cannabis industry. In addition to overseeing the financial function of the Company, I intend to contribute to THC’s visibility in the marketplace and emphasize shareholder value,” commented Hee Jung Chun.

Tracey St. Denis resigns from the position as CFO but will remain with the Company as its chief accountant. “We thank Ms. St. Denis for her services as CFO of the Company and look forward to continuing to work with her,” said John Miller, CEO of THC.

THC’s vision is to be on the leading edge of scientific research and development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available.
www.thcbiomed.com

President and CEO:

John Miller
THC Biomed Intl Ltd.
T: 604 682-1643
E: info@thcbiomed.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. Forward-looking statements in this press release include that (a) Hee Jung Chun’s appointment as CFO will be on an interim basis, (b) THC will become a major player in the Cannabis industry, (c) THC will be on the leading edge of scientific research and development of products and services related

to the medical cannabis industry while creating a standard of excellence, (d) as the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis and (e) THC will be in the forefront of this rapidly growing industry. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.